The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | The role of immunotherapy in the AML treatment landscape
In this video, Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, shares some insights into the role of immunotherapy in the treatment of acute myeloid leukemia (AML). Dr Cluzeau first comments on the importance of allogeneic stem cell transplantation (alloSCT) in AML, and then goes on to discuss the promise of novel immunotherapies, including CAR-T cells and antibodies. To conclude, Dr Cluzeau draws focus on the potential of magrolimab for the treatment of this disease and future outlooks. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
